about
Plant antimicrobial peptides as potential anticancer agentsInsect antimicrobial peptides: potential tools for the prevention of skin cancerHypericin in the Light and in the Dark: Two Sides of the Same CoinDrug Delivery Using Nanoparticles for Cancer Stem-Like Cell TargetingEnhancing the efficacy of cytotoxic agents for cancer therapy using photochemical internalisationInhibition of lipolysis by mercaptoacetate and etomoxir specifically sensitize drug-resistant lung adenocarcinoma cell to paclitaxelTFPI1 mediates resistance to doxorubicin in breast cancer cells by inducing a hypoxic-like responseThe reversal effects of 3-bromopyruvate on multidrug resistance in vitro and in vivo derived from human breast MCF-7/ADR cellsReducing Both Pgp Overexpression and Drug Efflux with Anti-Cancer Gold-Paclitaxel NanoconjugatesThe Tumor-Associated Variant RAD51 G151D Induces a Hyper-Recombination PhenotypeMicrofluidic cell isolation technology for drug testing of single tumor cells and their clusters.Novel delivery approaches for cancer therapeutics.Designing a broad-spectrum integrative approach for cancer prevention and treatment.The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells.Controlling the Master: Chromatin Dynamics at the MYC Promoter Integrate Developmental SignalingTargeting Intracellular Calcium Signaling ([Ca2+]i) to Overcome Acquired Multidrug Resistance of Cancer Cells: A Mini-Overview.Clear: Composition of Likelihoods for Evolve and Resequence Experiments.Regulatory functional territory of PLK-1 and their substrates beyond mitosis.Metalloproteinase dependent reduction of cell surface cluster determinants upon the induction of apoptosis.Drug resistance in cancer: an overview.When will resistance be futile?YY1 suppresses FEN1 over-expression and drug resistance in breast cancerA meta analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers.Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy.Spheroid-Formation (Colonosphere) Assay for in Vitro Assessment and Expansion of Stem Cells in Colon CancerA principle of organization which facilitates broad Lamarckian-like adaptations by improvisationDevelopment of a lytic peptide derived from BH3-only proteinsDiscovery of 'click' 1,2,3-triazolium salts as potential anticancer drugs.Effects of 1,25(OH)₂D₃ on Cancer Cells and Potential Applications in Combination with Established and Putative Anti-Cancer Agents.Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1.Drug-Loaded Polymeric Nanoparticles for Cancer Stem Cell Targeting.Molecular research in penile cancer-lessons learned from the past and bright horizons of the future?Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose.A short update on cancer chemoresistance.Cholangiocarcinoma: from molecular biology to treatment.An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer.Metabolomics applications in precision medicine: An oncological perspective.PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.Limiting the development of anti-cancer drug resistance in a spatial model of micrometastases
P2860
Q21284491-8EB9B6F7-48CE-416E-A18E-F004CAD4504DQ26740243-173495C2-6655-437F-92C2-C3B6DC48C934Q26747362-8196B577-B8A2-4EBB-B6D0-559B3B1D1A39Q26752688-3DF35CFD-2698-4347-AB93-AE3B4C8A5F93Q26998547-9C30EE16-B906-4DED-B315-655FA2FC370BQ28533247-E3AD7C0B-8981-4C9C-BE22-D33A235ED943Q28539226-1161FED2-93F3-4CA3-9E93-1C9145724B03Q28544747-903784DD-3E56-4C10-A37F-BC531DD45ED2Q28553214-2E313F82-630F-4DDD-A384-32DE0E301A75Q28553470-0F4C36E9-14D8-401B-BEA4-4504AC5AE4C7Q30364122-42A7A3D8-9011-4D17-92FA-3D56027268BEQ30368171-10DECF8B-76D0-46E6-91CA-0FB31B4B6EB2Q30736359-57F2A9D7-8ABF-469A-A7D5-EBB7C366CA21Q30837718-A178B3E5-73C1-4612-A324-822F3F99632EQ33608508-320B1E55-95A5-4704-BF1C-129ADD5040E1Q33737290-1074D0CE-6703-48F1-ADB2-E8FD3AF61627Q33877433-2B3889E7-A617-4991-85FF-336EB457C747Q33914204-82CF9DEA-C354-42A3-883D-84067D6A282FQ34086914-3282B1EE-0E82-4745-9274-6A8994F21AF7Q34437369-88F9C5FB-2816-4221-8493-51E3FBF375B9Q34715457-82D796C1-F981-455E-A16E-498BE1AC438DQ35143452-63D55504-D49B-4665-8869-B74D9562BF13Q35150412-0F8BA740-165F-4CAE-997E-5A69B91096C0Q35497448-1D393AEB-3F5A-405F-A15B-69D579EABDC2Q36024608-3C3310F9-52BD-4BB4-AEDE-17CA9B3C8A16Q36344038-9406D94D-C231-44FD-A880-E3B3F2FC186DQ37164293-71419D2C-D7C1-4F2B-9260-DDE04A02B2C1Q37258715-FC80E956-26E2-4C22-B0DE-4A3D22B2DCBAQ37628495-49E4F9F3-41D7-427D-83BD-F1C5FC5F2D8AQ37633542-46C9A6C9-4D5E-481C-AFD2-466A1864BF92Q37639772-F3FD616E-2A7E-481C-BFE5-087DE025B5A8Q38146645-F99AFA21-BD71-4F77-AAD4-C7AED37FC95DQ38213800-C1EAA1A3-C723-4E92-BA24-789E6CF332D3Q38253576-69134370-31B7-47CB-8944-C882A4A7CF72Q38597008-B0094DA9-BDF6-45A5-93EE-31ABB52FD77DQ38647794-0C5E0207-76C4-48BA-AD7F-33BD1ECD554CQ38654867-7BDCA79B-5756-43FE-894F-46FCEF89EE90Q38689857-60C685E4-213C-49F6-B0F1-EA45FDE13A44Q38718679-24BF5608-4D9F-4C5E-BC8B-689A31CC5E70Q38738084-A842FDC1-747C-4883-85D3-86011BC9C850
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Mechanisms and insights into drug resistance in cancer
@ast
Mechanisms and insights into drug resistance in cancer
@en
type
label
Mechanisms and insights into drug resistance in cancer
@ast
Mechanisms and insights into drug resistance in cancer
@en
prefLabel
Mechanisms and insights into drug resistance in cancer
@ast
Mechanisms and insights into drug resistance in cancer
@en
P2860
P356
P1476
Mechanisms and insights into drug resistance in cancer
@en
P2093
Hiba Zahreddine
Katherine L B Borden
P2860
P356
10.3389/FPHAR.2013.00028
P577
2013-03-14T00:00:00Z